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1. Introduction
Epigenetics is a branch of genetics that focuses on the heritable changes of DNA or associated
proteins, other than DNA sequence variations, which carry information content during cell
division [1,2]. These heritable changes are ascribed to chromatin, which constitutes the
ultrastructure of DNA and whose modifications affect the genetic material functionality.
Differences in chromatin structure have been associated to transcription regulation [3-5] and
chromosome stability [6,7], affecting both gene’s information, expression and heritability.
Noteworthy, these epigenetic modifications are involved in both transcriptional activation and
repression, indicating their widespread role as modulators of gene expression in numerous
biological processes [8,9].
Chromatin is subjected to numerous modifications roughly classified in two groups: DNA and
histone post-translational modifications (histone-PTMs).
DNA methylation is the most studied epigenetic modification of DNA and corresponds to the
covalent addition of a methyl (CH3) group to the nucleotide cytosine within CG dinucleotides
or CNG trinucleotides where N can be C, A, G or T. Usually, DNA methylation induces
decreased protein-DNA binding of transcription factors and leads to the repression of gene
expression [10].
DNA “methylable” sequences are not uniform across the human genome but restricted in CpG
rich DNA regions termed CpG islands (CGI). CGI are localized at repetitive sequences, heavy
methylated, to prevent the reactivation of endoparasitic sequences such as transposons, and
at gene promoter sequences, which are normally refractory to methylation in normal somatic
cells [8,11].
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DNA methylation is specifically established by DNA methyltransferases proteins (DNMTs),
which can be recruited by numerous DNA-binding molecular complexes. These enzymes were
classically classified in two categories: de novo DNMTs, as mammalian DNMT3a and DNMT3b,
in charge of the addition of the methyl group on a previously unmethylated DNA, and mainte‐
nance DNMTs, whose only known member is DNMT1, responsible for methylation renewal in
the newly synthesized DNA copy. However, this classification does not entirely explain methyl‐
ation establishment and maintenance in various molecular processes [10]. For instance, a number
of studies demonstrated that all DNMTs are important in the maintenance of methylation during
DNA replication, therefore indicating that it is not possible to distinguish classes of DNMTs based
on their functional role [12-15]. Another important functional role in DNA methylation dynam‐
ics is constituted by the removal of methyl group, which is required to activate methylated genes.
However, demethylation is a process not fully understood, in fact, until recently, it was current
opinion that only a passive demethylation could occur, as a consequence of a lack of methyla‐
tion maintenance during DNA replication. The discovery of several putative demethylases, as
thymine DNA glycosylase (TDG), methyl-binding domain 2 (MBD2), and GADD45 [16-18],
strongly suggested that an active mechanism of demethylation can occur in specific contexts, such
as germ line reprogramming [19-22].
The second group of epigenetic changes is represented by histone post-translational modifica‐
tions (PTM), which consist in the addition of chemical groups to amino acid residues of both
canonical histones (H2A, H2B, H3 and H4) and variant histones (such as H3.1, H3.3 and HTZ.1).
Differently from DNA modifications, there are at least eight distinct types of histone post-
translational modifications: acetylation, methylation, phosphorylation, ubiquitylation,
sumoylation, ADP ribosylation, deimination, and proline isomerization. Each chemical group
can be established at multiple amino acid residues of nucleosomes in multiple levels of
substrate modification by specific classes of enzymes. For example, lysine methylation can be
established at numerous aminoacidic residues of N-terminus tails of histones H3 and H4, such
as K4, K9, K20 and K27, in mono-, di- or tri-methylated forms. This variety of histone PTMs
and its timing of appearance depends on the particular cell conditions giving the cells different
functional responses [23]. Differently from DNA methylation, histone PTMs feature numerous
functional roles. For instance, histone acetylation regulates DNA replication, repair and
condensation; methylation, phosphorylation and ubiquitylation are involved in DNA repair
or condensation. Moreover, all PTMs regulate transcription processes; acetylation is generally
a marker of transcriptionally active genes, and methylation can be a marker of repressed or
active genes depending on the amino-acid residues involved. For example, methylation of
histone H3 lysine 4 (H3K4me) is considered a mark of transcriptionally active genes, while
methylation of histone H3 lysine 9 and 27 (H3K9me; H3K27) are considered a mark of
transcriptionally repressed genes [8,11,23].
Almost all cellular processes that require transcription dynamics and genetic stability can be
considered epigenetic processes. Cellular differentiation is a good example of biological proc‐
ess, which is strictly connected to epigenetics. The genome sequence is static and it is the same for
each cell of an organism (with some exceptions); however, cells are able to differentiate into many
different types, with different morphology and physiological functions. During organism
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development, the zygote, derived form a single fertilized egg cell, originates totipotent cells, able
to potentially differentiate in all cell types of adult organisms. After several divisions, totipotent
cells originate pluripotent cells, which are partially differentiated and able to differentiate in
several cell types. Finally, pluripotent cells complete differentiation becoming adult somatic cells.
The differentiation processes are characterized by transcriptional activation and repression of
specific genes and, once completed, the cells maintain their characteristic gene-expression pattern,
strictly dependent on the epigenetic modifications previously established [24]. Therefore, cell
differentiation is rigorously related to the establishment of the correct epigenetic status and to the
proper epigenetic maintenance. Epigenetic abnormalities alter gene expression, counteracting
regular differentiation and cell physiology [25]. In support of this theory, cancer cells feature an
aberrant epigenetic landscape, indicating the causal relationship between epigenome dynam‐
ics and cellular processes as proliferation, cellular identity maintenance and genomic instabili‐
ty. [26-28]. Frequently, CGIs in the proximity of tumor suppressor genes (TSG) are methylated in
various cancers, inducing TSGs transcriptional repression and promoting cancer progression
[29]. Furthermore, specific patterns of histones H3 and H4 acetylation and methylation are
associated with numerous cancer types, and it has been shown that several epigenetic patterns
enable to distinguish disease subtypes [30,31].
This chapter explores the role of the Enhancer of Zeste Homolog 2 (EZH2). EZH2, the catalytic
subunit of Polycomb repressive complex 2, catalyzes the addition of methyl groups to lysine
27 of the N-tail of histone H3 (H3K27me). The importance to specifically focus on EZH2 raises
from the evidence that it is involved in several differentiation processes and is often over-
expressed in a wide variety of cancer types [32].
2. PcG proteins and PRC-mediated silencing
Polycomb group proteins (PcG) were discovered in Drosophila melanogaster as responsible of
homeotic gene silencing, also referred as Hox clusters. Hox proteins are a group of transcrip‐
tion factors that determine cell identity along the anteroposterior axis of the body plan by the
transcriptional regulation of hundreds of genes [33-42]. After the initial discovery in fruit flies,
PcG proteins were detected in plants and in mammals, where they are involved in develop‐
ment, stem cell biology and cancer [43-48]. Polycomb-mediated gene silencing is required in
many processes like mammalian X-chromosome inactivation and imprinting [49,50]. Further‐
more, PcG proteins are required to maintain stem cell identity [51]. Indeed, their numerous
target genes encode for transcription factors and signaling components involved in cell fate
decision, therefore in differentiation processes [32].
Principal PcG proteins are conserved from Drosophila to human indicating that PcG-mediated
gene silencing is conserved among eukaryotes [42,52,53]. In mammals, each of the fly proteins
has two or more homologs [54]. PcG proteins form two main complexes: Polycomb-repressive
complex 1 and 2 (PRC1, PRC2) [55-59].
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In mammals PRC1 is formed by BMI1, RING1A/B, CBX, and PHC subunits [60]. RING1A/B
are ubiquitin E3 ligases that catalyze the monoubiquitylation of histone H2A at lysine 119
(H2AK119ub1), a histone PTM associated with transcriptional silencing [48,53].
As previously explained, PRC2 has a histone methyltransferase activity on lysine-27 of histone
H3 [56-59]. EZH2 is the catalytic subunit of the complex and is activated by other PRC2
subunits like EED, SUZ1 and RbAp46 [61,62]. Recent studies have identified an EZH2
homolog, EZH1 that originates an alternative PRC2 complex and, as EZH2, is able to methylate
H3K27. EZH1 and EZH2 can occupy similar target genes, and in some cases have been
proposed to play redundant roles. However, during development, it has been demonstrated
that the two proteins, can also have distinct and context-dependent roles [63-65].
PRC1 and PRC2 are able to induce gene silencing independently by each other [66,67] or by a
synergistic mechanism. In fact, establishment of H3K27me3 by PRC2 complex can induce the
recruitment of PRC1 by binding the chromodomain of the PHC subunits [39,58]. Once recruit‐
ed, PRC1 induces transcriptional repression of target gene by catalyzing the ubiquitilation of
lysine 119 of histone H2 or by an H2Aub-independent mechanism [68-70]. Therefore, in gene
promoters of PRC1 and PRC2 common target genes, H3K27me3, can be reckoned as the hall‐
mark of PcG mediated repression, whereas PRC1 carries out the gene silencing (Figure 1) [48,71].
Figure 1. Epigenetic gene silencing PcG-mediated. PRC2 induces EZH2-mediated H3K27me3. H3K27me3 recruits
PRC1 that ubiquitylates H2AK119 promoting chromatin compaction and gene silencing.
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For what concerns PRC1-independent target genes, it has been shown that PRC2 is able to
catalyze in vitro the methylation of lysine 26 of histone H1, which in turn recruits heterochro‐
matin binding protein 1 (HP1) to chromatin, influencing its structure [72,73].
PRC2 is also able to cooperate with other epigenetic silencing enzymes. Recent studies
demonstrated that it acts upstream of DNMTs in order to silence target genes [74]. The
mechanism is not yet clear, but a hypothesis is that target genes are initially repressed through
histone H3K27 methylation. Afterwards, PRC2 induces a more stable transcriptional silencing
by recruiting DNMTs and establishing CGI methylation [75-77]. Moreover, PRC2 associates
with histone deacetylases, reinforcing transcriptional repression and providing functional
synergy to stable silencing of target genes (Figure 2) [32,56-59,61,78,79].
The functional link between PcG proteins, HDACs and DMTs demonstrated a synergic control
of gene silencing involved in both physiological and pathological processes.
Figure 2. Functional link between PRC2 HDACs and DNMTs. Target genes are initially deacetylated by a histone
deacetylase. PRC2 silences target genes by H3K27me3. PRC2 may also recruit DNMTs that methylate DNA promoting a
more strongly silenced chromatin state.
3. Regulation of PRC2 activity
Polycomb group proteins are epigenetic regulators of embryonic development and stem cell
maintenance [48,51,80] and their deregulation contributes to cancer [28,81]. The crucial role of
Polycomb-repressive complexes in the regulation of these biological processes strongly
supports the presence of multiple molecular mechanisms involved in PRC activity modulation,
such as regulation of expression, post-translational modification and recruitment of other
molecular complexes to target genes.
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3.1. Regulation of PRC2 components expression
As already explained, PRC2 functions are strictly tissue-specific. Therefore, it should not
surprise that the expression of PRC2 subunits has been reported to be context- and tissue-
specific, despite the activity of PRC2 promoters has not yet fully understood. Recently, it has
been proposed a general rule by which PRC2 expression is maintained by molecular factors
that control cell proliferation and self-renewal, such as E2F factors and c-myc, whereas its
transcriptional repression is induced by differentiation-promoting factors, such as pRb and
p16INK4b [65,82-85].
For what concerns the transcriptional regulation by the pRb/E2F pathway, it has been dem‐
onstrated that E2F factors are required for the transcriptional activity of EZH2 and EED in
mouse embryonic fibroblasts (MEF). Ectopic expression of pRb and p16INK4b, both involved
in E2F target gene repression, induces PRC2 subunits transcriptional repression, whereas pRb
silencing increases their transcript levels [82-84].
Furthermore, it has been recently reported that c-myc, a key regulator of ES cells pluripotency
maintenance, is directly involved in transcriptional upregulation of all components of PRC2;
c-myc binds PRC2 subunits promoters and induces the acetylation of histones H3 and H4, an
epigenetic modification involved in transcriptional activation [85].
Finally, it has been demonstrated that EZH2 is post-transcriptionally regulated by a micro‐
RNAs-mediated translation-inhibition mechanism. MicroRNAs (miRNAs) are small non-
coding RNA ~22 nt long (ncRNA), involved in various biological processes, which exert gene
expression regulation. Several studies showed a role of miRNA in chromatin structure, they
are indeed able to regulate transcriptional levels of epigenetic enzymes as for example PcG
proteins [86,87]. Initially, it has been shown that miRNA-101 and miRNA-26a negatively
regulate EZH2 expression by binding to its 3’-UTR. However, recent studies have reported an
increasing number of miRNAs, able to inhibit the translation of PRC2 subunits (reviewed in
[87]). For example, miR-214 regulates EZH2 expression during muscle differentiation [88].
Furthermore, downregulation of several miRNAs promotes EZH2 overexpression in cancer;
for instance, miR-25 and miR30d in thyroid carcinoma [89], let-7 in prostate cancer [90], miR-98
and miR-214 in esophageal squamous cell carcinoma.
3.2. Post-translational modification of EZH2
Several studies demonstrated that post-translational modifications of PRC2 subunits can
regulate their recruitment to target genes and molecular activity [91-93].
The first post-translational modification that will be analyzed is EZH2 phosphorylation, which
has been extensively studied. In order to bind to PRC2 complex and exert its molecular
function, EZH2 must be phosphorylated in several specific sites. EZH2 phosphorylation can
be classified in two groups: dependent by cell-cycle-dependent signals and dependent by
extracellular-regulated kinases [94]. In the first mechanism, EZH2 is phosphorylated by Cdk1
and Cdk2 during cell cycle progression [92,93,95]. In murine model, phosphorylation of
threonine 345 (Thr345) increases the binding of EZH2 to specific regulatory ncRNAs as
HOTAIR that induces the recruitment of PRC2 to HOX gene promoters, and Xist RepA that
Chromatin Remodelling124
induces the inactivation of X chromosome [93]. In humans, phosphorylation of threonine 350
(Thr350) corresponds to murine Thr345. Recently, Chen and collaborators demonstrated a
crucial role for the phosphorylation of Thr350 by Cdk1 and Cdk2 in both EZH2-dependent
gene silencing and EZH2-mediated cell proliferation and migration [92].
Moreover, Cdk1 is able to phosphorylate EZH2 at Thr487. This modification is associated with
the disruption of EZH2 binding with other PRC2 components with subsequent methyltrans‐
ferase activity inhibition [95]. Surprisingly, these data are in contrast with studies of Kaneco
and coworkers, which demonstrated that EZH2 phosphorylated at Thr487 is able to bind other
subunits of PRC2 complex and to maintain its activity. In addition, another recent work
showed that inhibition of Cdk1 suppresses hoxA gene expression in contrast to the findings
of Chen and colleagues. [92,93,95]. Bearing in mind that these three findings use different models
to analyze EZH2 phosphorylation, becomes noticeable that the apparent discrepancies could
be explained with different mechanisms of tissue-specific regulation. Further studies are
needed to resolve these specific incongruities. Mechanisms of EZH2 regulation during cell
cycle are summarized in figure 3.
Figure 3. Model for regulation of EZH2 activity during cell cycle. PRC2 subunits are E2Fs target genes. E2Fs activity
is inhibited by hypo-phosphorylated pRb during G1 phase of cell cycle. Activity of Cdk/cyclin complexes triggers the
transition from G1 to S phase through phoshorylation of pRb and consequent activation of E2F target genes. More‐
over Cdk2 and Cdk1 are able to phosphorylate EZH2 promoting the binding of ncRNA, a crucial step for the recruit‐
ment of PRC2 to its target genes.
Phosphorylation of EZH2 is also modulated by environmental signals. Extracellular signals
induce Akt activation that in turn is able to phosphorylate EZH2 at Serine 21 (Ser21), which
results in a suppression of the PRC2 activity. Differently by previous phosphorylation
mechanisms, Akt-dependent phosphorylation does not affect the binding with other PRC2
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components but it reduces the affinity of EZH2 with histone H3, which results in a decrease
of the H3K27 methylation and consequent de-repression of the EZH2-silenced genes [96].
Furthermore, recent studies reported that EZH2 can be phosphorylated at threonine 372
(Thr372) by p38α kinase in muscle stem (satellite) cells in response to tumor necrosis factor
(TNF), an inflammatory cytokine highly expressed in muscle regeneration process [97]. The
phosphorylation of EZH2 at Thr372 promotes the repression of Pax7, a marker of stem cells,
by inducing the interaction between PRC2, YY1 and PRC1. This leads to the transcriptional
activation of genes involved in muscle regeneration and to transcriptional repression of genes
involved in cell proliferation. This data are in apparent conflict with the fully studied role of
EZH2 in the cell proliferation promotion, but it is possible that in response to specific signals
and in particular cell types, PRC2 can silence genes involved in cell cycle regulation, resulting
in an antiproliferative activity [97]. Other studies are needed to confirm this hypothesis.
Finally EZH2 and SUZ12 can be sumoylated in vitro and in vivo but the role of this modification
is still not yet clear [91].
3.3. PRC2 recruitment to target genes
PRC2 core subunits bind to the DNA sequences with low affinity, this, therefore, suggests the
existence of recruiting mechanisms that direct PRC2 to target genes [98].
In Drosophila melanogaster, PcGs are recruited by Polycomb response elements (PREs), DNA
sequences of several hundred base pairs [42,48,99] located both in proximal region of gene
promoters and in long-range enhancer elements. PREs contain consensus sequences for
various transcription factors [100]. For instance, Drosophila’s pleiohomeotic (PHO) and
pleiohomeotic-like (PHO-like) are PcG proteins conserved in mammalian cells and involved
in the recruitment of PRC complexes.
It is important to stress that PREs are element and not short stretches of nucleotides and contain
numerous TF binding sites, therefore, although several Drosophila transcription factors are
essential for the recruitment of PRC complexes to specific promoters, a single TF is not
sufficient alone. Moreover, “universal” factors able to bind all PcG target genes have not been
found yet, and it is strongly suggested that the PcG protein recruitment is a cell type-specific
mechanism dependent by various combinations of TFs [52,53]. Mammalian PREs have been
just recently discovered [101]. The mammalian orthologue of Drosophila DNA-binding protein
PHO is YY1, however, studies in mouse stem cells showed a little overlap between sequences
bound by YY1 and PRC2 suggesting a cell-type specific role rather than a general one [47].
Similar to YY1, the embryonic stem (ES) cell-related transcription factors OCT4, SOX2 and
NANOG co-occupy a subset of PcG target genes in human and mouse ES cells [45,46].
Interestingly, recent studies demonstrated that the serine/threonine protein phosphatase-1
(PP1), together with its regulatory partner NPP1, is capable of complexing PRC2 at its target
genes, modulating the DNA occupancy of EZH2 and therefore its activity [102].
Current data suggest that, similarly to flies, various transcription factors may be involved in
the recruitment of mammalian PRC2, varying in different cell types and context. Recent studies
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showed that Twist-1 recruits EZH2 at ARF-INK4a locus in Mesenchymal Stem Cells (MSCs),
inducing transcriptional repression of both p14ARF and p16INK4a, and suppression of
senescence initiation [103].
Moreover, PRC2 can also be associated with another PcG protein, called PHF1. PHF1 is not a
core subunit of PRC2 but its association with the complex influences the recruitment of PRC2
to target genes and stimulates the enzymatic activity [104,105].
Furthermore, several reports have identified in mouse and human ES cells, a novel DNA-
binding component of PRC2 complex, Jarid2, which is a member of the Jumonji C (JmjC) family
that binds GC and GA-rich motifs [106-109]. Despite this, it has been demonstrated that Jarid2
promotes PRC2 recruitment to target genes, but its precise role in PRC2 activity has not yet
been defined. Knockdown of Jarid2 causes an increase of H3K27me3 levels on some PRC2-
target genes [106,107] and a decrease on others [108,109]. Different effects of Jarid2 on PRC2
activity could depend from additional factors, and it has been suggested that it acts as a
‘‘molecular rheostat’’ that finely calibrates PRC2 functions at developmental genes [106].
Finally, long ncRNAs have been implicated in the recruitment of PRC2 [48,53,80,81,110]. For
example, in primary human fibroblasts the ncRNA HOTAIR recruits PRC2 complex to HOXD
locus for regulating gene silencing in trans [111]. Several long ncRNA have been discovered and
its tissue-specific expression allows assuming PRC2-dependent roles in organogenesis [112].
4. Role of PRC2 in differentiation and cell fate commitment
In past decades, several studies demonstrated that PcG proteins play a key role during
invertebrate differentiation but, only recently, the involvement of these proteins during
vertebrate organogenesis as regulators of developmental gene expression has been confirmed.
Various tissues are regulated by PRC2 during development (Table 1).
Embryonic stem cells (ESC) are able to differentiate into all derivatives of the three primary
germ layers and their pluripotency is preserved by the inhibition of differentiation and the
promotion of proliferation [71]. Therefore, ESC can be an extremely valuable model to study
cell fate transition mechanisms involved in mammalian development. As previously ex‐
plained, during development, epigenetic changes regulate the activation determining cell fate.
Genome wide analysis revealed that epigenetic changes regulate the activation or the inhibi‐
tion of lineage-specific transcription factors in cell fate transition, suggesting their role in the
maintenance of ESC pluripotency. For what concerns the polycomb repressive complexes, they
occupy gene promoter sequences of the main developmental genes, impeding their transcrip‐
tional activation through repressive marks [44-46].
Major targets of PRC2 are tumor suppressor genes, such as Ink4b/Arf/Ink4a locus and their
inhibition promotes cell proliferation [44,132,136-141].
In ESC, numerous differentiation-related genes feature a bivalent epigenetic regulation in
preparation of lineage commitment [65]. This bivalent epigenetic regulation consists in the
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presence of both H3K27me3 and H3K4me3, which respectively are a repressing and an
activating mark of transcription [142]. Upon differentiation, PRC2 complex dissociates from
these gene promoters, inducing H3K27me3 removal and gene expression [45,46].
Similarly  to  ESC,  PRC2  is  involved  in  organ  development  through  tissue-dependent
mechanisms.  As  a  general  rule,  EZH2  prevents  differentiation  by  inhibiting  genes  in‐
volved in  its  completion.  For  instance,  EZH2 negatively  regulates  skin  development  by
repressing premature  differentiation of  skin  progenitors.  Specifically,  it  has  been shown
that  in  this  specific  differentiation  model,  EZH2  prevents  epidermal  differentiation  by
inhibiting  the  recruitment  of  AP1,  a  transcriptional  activator,  to  Ink4/ARF  locus,  thus
maintaining proliferative  potential  of  epidermal  progenitors  [120].  Likewise,  it  has  been
reported that silencing of EZH2 in hepatic stem/progenitor cells promotes the differentia‐
tion into hepatocytes and further enhances the maturation of hepatocytes through Ink4a-
Ink4b dependent and independent mechanisms [130].
EZH2 also contributes to pancreatic regeneration, by the suppression of Arf/Ink4a locus and
the promotion of pancreatic β-cells proliferation, [132] and to terminal differentiation inhibi‐
tion of mammary gland alveolar cells during pregnancy, in order to prevent milk production
and secretion until parturition [135].
In opposition to PRC2-dependent mechanisms mentioned above, there are some tissues and
organs, which require PRC2 activity for differentiation completion. For instance, recent studies
showed a promoting role of EZH2 methyltransferase activity in adipogenesis. EZH2 is
required, indeed, for silencing of Wnt1, -6, -10a, and -10b genes, which are inhibitors of
adipogenesis [134]. Moreover, EZH2 contributes to the correct development by preventing the
inappropriate gene expression, typical of different cell types. The cardiac differentiation is an
example of this PRC2-dependent regulatory function; indeed, EZH2 is involved in transcrip‐
Tissue Specie Role/Stage References
Brain humanmouse
Neuronal stem cell maintenance; oligodendrocytes
differentiation [113-118]
Spinal Cord chicken Dorsoventral patterning [119]
Skin humanmouse
Epidermal stem cell maintenance; hair follicle
homeostasis [120-122]
Cardiac Muscle mouse Endocardial cushion formation and cardiomyocyteproliferation [123-125]
Skeletal Muscle mouse Skeletal muscle stem cells maintenance; somitesdeveloping and myoblasts proliferation [88,126-129]
Liver mouse Hepatic stem/progenitor cells proliferation andself-renewal [130,131]
Pancreas mouse β-cell proliferation [132,133]
Adipose Tissue mouse Adipogenesis promotion [134]
Mammary Gland mouse Alveolar progenitors maintenance [135]
Table 1. Tissues under PRC2 regulation
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tional repression of genes as Six1, responsible of skeletal muscle genes activation in cardio‐
myocytes. EZH2-knockout mice feature postnatal myocardial pathologies and altered cardiac
gene expression [123,125]. EZH2 promotes evenly, by indirect mechanism, liver differentiation
by the inhibition of Pdx1 gene, which is involved in pancreatic differentiation promotion [133].
The complexity of PRC2-dependent molecular pathways in organogenesis has been specifi‐
cally demonstrated by extensive studies in neurogenesis and myogenesis.
4.1. Role of EZH2 in neurogenesis
Neurons and astrocytes derive from common neural precursors (neuronal stem cells: NSC),
which sequentially pass through phases of expansion, neurogenesis and astrogenesis. The
timing of the switch from neurogenic to astrocyte differentiation is crucial for the determina‐
tion of neuron numbers.
Analysis of EZH2 expression in neurogenesis showed that EZH2 decreases when NSCs
differentiate into neurons and is completely suppressed in astrocyte differentiation. In
contrast, EZH2 expression remains high in oligodendrocyte differentiation, from precursor
cells to the immature stage [113]. EZH2 silencing and overexpression in NSCs confirmed these
results, indeed forced expression of EZH2 increases the number of oligodendrocytes and
reduces the number of astrocytes [113]. Furthermore, forced expression of EZH2 in astrocytes
induces a partially dedifferentiation to NSCs [117], supporting a key role for EZH2 towards
oligodendrocyte commitment. For what concerns EZH2 silencing, it has been reported that
inhibition of EZH2 or EED in neural precursor cells extends neurogenic phase, inducing an
increased production of neurons and a delay in gliogenesis [114]. However, Pereira and
colleagues found that loss of EZH2 results in a shift from self-renewal towards differentiation,
accelerating the timing for both cortical neurogenesis and gliogenesis [115]. These differences
could be accounted to differential EZH2 inhibition timing before or after neurogenesis onset;
further studies are required to clarify this pathway, but all data confirm an essential role for
PRC2 in the regulation of developmental transitions timing.
4.2. Role of EZH2 in skeletal myogenesis
Proliferation  and  differentiation  of  skeletal  muscle  cells  are  controlled  by  a  family  of
myogenic  transcription  factors,  known  as  bHLH  proteins.  MyoD  is  one  of  the  most
important bHLH factors, which is crucial for complete muscle differentiation [143]. In ESC,
PRC2 binds and represses numerous MyoD target genes [46]. In skeletal myoblasts, despite
MyoD  expression,  PRC2  is  recruited  by  YY1  to  muscle-specific  genes,  inhibiting  their
expression and preventing premature differentiation. After the commitment of myogene‐
sis,  EZH2 expression decreases  and H3K27me3 at  MyoD-target  loci  is  removed.  Conse‐
quently,  muscle-specific  genes  are  transcriptionally  active  [126].  This  process  is  finely
regulated  by  miR-214,  a  miRNA  expressed  after  myogenic  commitment  of  MyoD.  In
myoblasts,  PRC  complexes  occupy  and  repress  transcription  of  the  intronic  region
containing miR-214.  During myogenesis decreased levels of  EZH2 allow derepression of
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the miR-214 locus. miR-214, on the other hand, targets EZH2 3‘UTR reducing its mRNA
translation, thus inhibiting EZH2 mRNA translation [88].
It has been shown that UTX, a specific demethylase that accomplish the muscle specific genes
activation, is specifically involved in removal of H3K27me3 and in establishment of H3K4me3,
an epigenetic marker of active genes [127].
Interestingly, EZH1 expression increases during myogenesis and its levels remain elevated in
differentiated myoblasts [144]. It has been demonstrated that PRC2-EZH1 complex has a
crucial role in the correct timing of transcriptional activation of muscle specific genes, as
myogenin, allowing proper recruitment of MyoD on its target promoters. This mechanism
involves another epigenetic modification, the phosphorylation of serine 28 of the histone H3
(H3S28ph), which is fundamental for the displacement of the PRC2-EZH2 complex [129].
This example proves the complexity of PRC2 dependent mechanism during development and
demonstrates how distinctive complexes can regulates various stages of differentiation.
Despite the numerous roles of PRC2 in differentiation and organogenesis are attributable to a
tissue-specific behavior, further studies are required to clarify each time its role in any process
of differentiation.
It is certainly clear that both PRC2 and its catalytic subunit EZH2 can be defined as key factors
in the regulation of development and in preserving cell identity.
5. EZH2 and cancer
Epigenetic abnormalities lead to altered gene expression and cellular physiology and occur in
several pathologies such as cancer [145,146]. Cancer epigenetics is a branch of cancer biology
that focuses on the epigenetic malfunctions involved in cancer initiation and progression [11].
EZH2 is differentially expressed in many tumors with abnormally elevated levels in cancer
tissues versus the corresponding normal ones. Of interest is that EZH2 expression is generally
correlated with metastatic cancer cells and poor prognosis [32].
Microarray studies in breast and prostate cancers were the first reports addressing the
implication of EZH2 in tumor progression [79,147]. Currently, a wide number of human
cancers associated with the deregulation of EZH2 have been discovered (Table 2).
The role of PcG proteins in cancer epigenetics is partially attributed to their contribution in
transcriptional repression of INK4b-ARF-INK4a locus, which encode p15INK4b, p16INK4a
and p14ARF proteins. These proteins constitute a homeostatic mechanism that protect
organism from inappropriate growth signals, which would eventually lead to uncontrolled
proliferation, promoting in contrast senescence or apoptosis [139]. Various tumors are
characterized by mutations or transcriptional repression at INF4b-ARF-INKa locus, which is
frequently a consequence of an aberrant epigenetic landscape established by factors as EZH2.
p15INK4b and p16INK4a are cyclin-dependent kinase inhibitors (CdkI) that function up‐
stream in the retinoblastoma protein (pRb) pathway. pRb can be found in two isoforms: hypo-
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phosphorylated pRb is the biologically active form, while hyper-phosphorylated pRb is
inactive. Hypo-phosphorylated pRb binds and inhibits E2F transcriptional factor activity.
Cdks, through phosphorylation of pRb, render E2F an active transcriptional activator on the
E2F target genes. INK4 proteins bind Cdk4 and Cdk6, blocking the assembly of catalytically
active Cyclin–Cdk complexes.
The result of an elevated transcription of INK4 proteins is a pRb-dependent cell-cycle arrest
in G1-phase [44,132,136-141,188,189]. Differently from INK4 proteins, p14ARF activates p53
pathway by inhibiting MDM2 functions. Indeed, MDM2 modulates p53 activity by inducing
its transcriptional repression and by promoting its proteasome-mediated degradation.
p14ARF induction generally causes cell-cycle arrest in G1 and G2 phases and apoptosis
[139,190,191]. Interestingly, EZH2 activity on p16INK4a promoter is Rb family-dependent.
Indeed, EZH2 is not able to bind INK4a locus in Rb proteins-deficient cells. A model has been
proposed where pRb recruits PRC2 to the p16INK4a promoter, which in turn promotes its
transcriptional repression [192].
EZH2 has shown a functional role evenly on pRb2/p130. pRb2/p130 is a member of Rb family
that binds and recruits HDAC1 at Cyclin A promoter, inducing gene silencing. Cyclin A is a
protein with a crucial role in cell cycle advancement. EZH2 competes with HDAC1 for its
binding with pRb2/p130, disrupting both proteins occupancy on cyclin A promoter, inducing
cyclin A activation and cell cycle progression [193,194].
As well as Rb family members, EZH2 inhibits tumor suppressor genes as p21 and phosphatase
and tensin homolog (PTEN) [170,195]. For example, oncogenic stimuli in melanocytes provoke
an oncogene-induced senescence, termed melanocytic nevus, which is a benign precursor of
melanoma. EZH2 overexpressing cells escape senescence through the inhibition of p21. EZH2
depletion indeed, results in p21 activation and senescence induction in human melanoma cells
[195]. A similar functional role has been reported in B-cell acute lymphoblastic leukemia (B-
ALL) cells, where EZH2 overexpression induces p21, p53 and PTEN silencing whereas its
knockdown induces cell cycle arrest and apoptosis [170].
As already stated, EZH2 is involved in apoptosis regulation [196,197]. High levels of EZH2
induce silencing of DAB2IP, a Ras GTPase-activating protein that promotes apoptosis through
the tumor necrosis factor-mediated JNK signaling pathway [196], and Bim, a protein that
promotes E2F1-dependent apoptosis [197].
DAB2IP is downregulated by epigenetic modifications in multiple aggressive cancers such as
lung, breast and prostate. In medulloblastoma, EZH2-dependent-DAB2IP repression corre‐
lates significantly with a poor prognosis, independent by the metastatic stage [187].
Recent reports, using genome-wide technologies, reported that a large number of differentia‐
tion-related factors are PRC2-target genes [43-47]. Consequently, numerous differentiation-
related factors as Gata, Sox, Fox, Pou, Pax, components of Wnt, TGF-β, Notch, FGF and retinoic
acid pathways are silenced by EZH2 [32,44-46]. It has been proposed that similarly to ESC, the
role of EZH2 in cancer is linked to its activity in self-renewal promotion and in the maintenance
of undifferentiated state of cells; EZH2 deregulation indeed, strongly contributes to the
transcriptional silencing of tumor suppressor and differentiation genes, promoting therefore
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uncontrolled cell proliferation and cancer progression [32]. For instance, EZH2 is upregulated
in Rhabdomyosarcoma (RMS) cell lines and primary tumors [180]. RMS is a tumor that arises
from muscle precursor cells, characterized by a partial myogenic differentiation. RMS cells do
not form functional muscle units and feature a strong proliferative ability. Specifically, as
shown in a recent study, EZH2 binds and silences several muscle gene promoters evenly under
differentiated conditions. The silencing of EZH2 promotes the reduction of H3K27me3
establishment, the recruitment of elongating RNA Polymerase II at these loci and the activation
of muscle specific genes, with a partial recovery of skeletal muscle phenotype [182].
Finally, PRC2 complex inhibits the expression of several tumor suppressor miRNA. For
instance, downregulation of miR-31, a common event of various melanomas, is caused by
epigenetic silencing of EZH2-mediated histone methylation [177].
Moreover, in metastatic liver cancers, up-regulation of EZH2 inhibits miR-139-5p, miR-125b,
miR-101, let-7c, and miR-200b, promoting cell motility and metastasis-related pathways [163].
















Brain Nervous Tissue [186,187]
Table 2. Human cancers associated with overexpression of EZH2
5.1. Extra-nuclear function of EZH2
The role of EZH2 as chromatin regulator has been extensively analyzed in a number of normal
and pathological models. Recent studies demonstrated a localization of EZH2 and other PRC2
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components in the cytoplasm of murine and human cells [198]. Cytoplasmic EZH2 maintains
its methyltransferase activity and interacts with Vav1, a GDP-GTP exchange factor (GEF) for
members of the Rho-family of GTPases. EZH2-Vav1 complex is necessary for actin reorgani‐
zation and cellular proliferation in T-lymphocytes and fibroblasts, promoting cytoskeletal
dynamics and cell migration as well as proliferation [198]. An example of this specific cyto‐
plasmic function could be found in prostate cancer cells, characterized by increased levels of
both nuclear and cytoplasmic EZH2. Cytoplasmic EZH2 might influence cell adhesion and
migration, contributing to invasiveness and metastatic ability of tumors [199,200]. The nuclear
and cytoplasmic functions of PRC2 thereby could co-operate to promote tumorigenesis.
5.2. Tumor suppressor roles of EZH2
Up to few years ago, EZH2 and PRC2 upregulation were assumed to hypermethylate H3K27,
repressing the transcription of tumor suppressor genes. In 2010, Morin and colleagues
identified a somatic mutation (Tyr641), which affects the EZH2 catalytic domain activity in
diffuse large B-cell lymphoma but not in mantle cell or T-cell lymphoma. Specifically, muta‐
tions in lymphoma were heterozygous but haploinsufficient for the enzymatic activity,
resulting in global deficit of H3K27 methylation and derepression of gene expression [168]. It
has been supposed that the loss of EZH2 in lymphoma may lead to derepression of genes,
promoting cell growth [201]. Other reports demonstrated that specific mutations in the EZH2
enzyme display limited capacity to carry out H3K27 monomethylation but have high efficiency
for driving di- and tri-methylation. In B-cell lymphomas, mutant and wild type EZH2 co-
operate increasing the trimethylated form [202].
Although the data analyzed as of now allow us to classify EZH2 as an oncogene, it must be
stated that in particular cellular environments the picture becomes less clear, like for example
in malignant myeloid diseases. Three different reports showed the inactivation of EZH2 in
myelodysplastic syndromes (MDSs) and in myeloproliferative disorder (MPD) [203-205].
Point mutations of EZH2 gene in MDSs, MPD, and primary myelofibrosis (PMF) are predictors
of poor overall survival, independently by risk factors [206,207]. Similarly, three studies
conducted in T-acute lymphoblastic leukemia (T-ALL) demonstrated that PRC2 displays a
tumor suppressor role in this pathology [171,208,209]. Particularly, Simon and colleagues
demonstrated that in mouse, loss of EZH2 in hematopoietic stem cells induces aggressive T-
ALL. Similar studies in human showed a comparable decrease of EZH2 levels in T-ALL [171].
Moreover, Ntziachristos and coworkers found that EZH2 and other PRC2 core components
are frequently mutated in T-ALL samples [209]. Of interest is that the frequency of PRC2
mutations is higher in pediatric subtype of leukemia [208].
Despite mutations of EZH2 seem specific for a few type of cancers, latest reports suggest
a  fine  balance  of  H3K27  methylation,  necessary  for  normal  cell  growth.  Recent  studies
showed an indirect EZH2-dependent mechanism involved in pancreatic cancer inhibition.
Jon Mallen-St. and co-authors investigated the role of EZH2 in pancreatic regeneration and
in cancer progression using a mouse model characterized by KRas activation, frequently
mutated  in  pancreatic  tumors.  In  particular,  they  show that  KRas  mutated  mice  devel‐
oped preneoplastic lesions but rarely progressed into invasive adenocarcinoma. The loss
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of  EZH2 function  in  this  experimental  model  increases  by  6  times  the  development  of
pancreatic  intraepithelial  neoplasia,  suggesting  a  protective  role  of  EZH2  in  pancreatic
carcinogenesis.  Since  EZH2  is  transiently  upregulated  after  injury  and  returns  to  basal
levels after tissue recovery, it  has been proposed that, in injured tissue, surviving acinar
cells  de-differentiate  into  metaplastic  epithelial  intermediates  are  able  to  proliferate  and
restore pancreatic injury. Proliferation is induced by EZH2 activation through P16INK4a
inhibition.  Subsequently,  acinar  cell  mass  and  function  is  finally  restored  through  re-
differentiation,  which  corresponds  to  restored  basal  levels  of  EZH2.  EZH2  is  involved
therefore in homeostatic mechanisms that controls pancreatic regeneration, decreasing the
risk of pancreatic cancer in patient with chronic pancreatic injury [156,184].
6. Conclusions
Epigenetic alterations in cancer cells represent an important aspect of tumor biology. Differ‐
ently from genetic modifications, epigenetic alterations can be reversed by specific drugs
inducing the restoration of “normal” cellular pathways, which in turn promote cellular
senescence or apoptosis. Therefore, epigenetic changes are excellent target candidates for
chemotherapeutic intervention in cancer.
Several HDAC and DNMT inhibitors are already available as putative anticancer drugs, and
several clinical trials are underway [210,211].
A pharmacological therapy, which specifically targets EZH2, may constitute a novel approach
to the treatment of cancer, assuming its role in inhibition of several tumor suppressor or
differentiation genes.
Recently, an S-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitor, 3-Deazaneplanocin A
(DZNep), has been demonstrated to deplete EZH2 and remove H3K27me3 at PRC2 target
genes. The inhibition of AdoHcy hydrolase fosters accumulation of AdoHcy, which in turn
stops S-adenosyl-L-methionine (SAH)-dependent methyltransferases.
DZNep promotes apoptosis in cancer cell lines as breast and colorectal cancer cells, but not in
normal cells. DZNep reduces cellular levels of PRC2 subunits, inhibits H3K27 methylation and
promotes the reactivation of PRC2 silenced genes and apoptosis [212]
Of interest is that, in several non-small cell lung cancer (NSCLC) cell lines, DZNep treatment
results in p27 accumulation, G1 cell cycle arrest and apoptosis, whereas immortalized
bronchial epithelial and fibroblast cell lines are less sensitive and show apoptosis with lesser
extent, which render it a potential candidate in anti-cancer therapy [160].
Studies in various gastric cancer cell lines and in primary human gastric cancer cells showed
that the DZNep responsiveness is attenuated in p53-depleted cells. p53 genomic status is
therefore a potential predictive marker of DZNep response in this specific cell type [213].
Despite its potential usefulness in cancer therapy, further studies need to address its target
specificity. Indeed, it has been reported that DZNep inhibits H4K20 methylation, another
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epigenetic modification, which is involved with chromosome stability [212]. The effect of
DZNep on several methyl transferases activity is a strong limiting factor for its use as anti-
cancer drug.
New PRC2 targets have been recently developed. GSK126 is a small molecule, competitor of
S-adenosyl-L-methionine. Unlike DZNep, that reduce levels of EZH2 indirectly, GSK126
specifically inhibits EZH2 methyltransferase activity with no alterations in EZH2 expression.
In lymphoma cells, GSK126 treatment decreases global H3K27me3 levels and reactivates PRC2
target genes. [169]. Finally, it has been discovered a natural compound, 16-hydroxyclero‐
da-3,13-dien-15,16-olide (PL3), which is able to promote apoptosis in leukemia K562 cells by
the modulation of various histone-modifying enzymes among which EZH2 and SUZ12 [214].
Other studies are needed to design inhibitors specific for PRC2 and to develop new strategies
for epigenetic therapy in cancer.
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